Sartorius Stedim Biotech S.A. (SDMHF)
USD 201.5
(0.0%)
USD 201.5
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.56 Billion EUR | 246.65% |
| 2022 | 1.02 Billion EUR | 155.92% |
| 2021 | 401.89 Million EUR | -23.74% |
| 2020 | 527.02 Million EUR | 389.34% |
| 2019 | 107.7 Million EUR | -14.29% |
| 2018 | 125.66 Million EUR | -1.15% |
| 2017 | 127.11 Million EUR | 88.14% |
| 2016 | 67.56 Million EUR | -21.83% |
| 2015 | 86.42 Million EUR | -1.15% |
| 2014 | 87.43 Million EUR | -32.72% |
| 2013 | 129.95 Million EUR | 14.31% |
| 2012 | 113.68 Million EUR | 13.56% |
| 2011 | 100.11 Million EUR | -2.57% |
| 2010 | 102.75 Million EUR | 17.24% |
| 2009 | 87.64 Million EUR | -41.59% |
| 2008 | 150.05 Million EUR | -2.46% |
| 2007 | 153.83 Million EUR | 182.85% |
| 2006 | 54.38 Million EUR | -10.43% |
| 2005 | 60.72 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 2.2 Billion EUR | -4.7% |
| 2024 Q1 | 2.49 Billion EUR | -30.06% |
| 2024 Q2 | 2.46 Billion EUR | -1.15% |
| 2023 Q1 | 1.21 Billion EUR | 17.92% |
| 2023 Q2 | 1.24 Billion EUR | 2.95% |
| 2023 Q3 | 3.69 Billion EUR | 195.91% |
| 2023 Q4 | 3.56 Billion EUR | -3.5% |
| 2023 FY | 3.56 Billion EUR | 246.65% |
| 2022 Q1 | 465.8 Million EUR | 15.9% |
| 2022 FY | 1.02 Billion EUR | 155.92% |
| 2022 Q2 | 576.1 Million EUR | 23.68% |
| 2022 Q3 | 1.02 Billion EUR | 77.07% |
| 2022 Q4 | 1.02 Billion EUR | 0.82% |
| 2021 Q3 | 416.3 Million EUR | 17.2% |
| 2021 Q4 | 401.89 Million EUR | -3.46% |
| 2021 FY | 401.89 Million EUR | -23.74% |
| 2021 Q1 | 459.8 Million EUR | -12.76% |
| 2021 Q2 | 355.2 Million EUR | -22.75% |
| 2020 Q2 | 243.3 Million EUR | 426.62% |
| 2020 Q1 | 46.2 Million EUR | -57.1% |
| 2020 FY | 527.02 Million EUR | 389.34% |
| 2020 Q4 | 527.02 Million EUR | 219.99% |
| 2020 Q3 | 164.7 Million EUR | -32.31% |
| 2019 Q4 | 107.7 Million EUR | 1.41% |
| 2019 FY | 107.7 Million EUR | -14.29% |
| 2019 Q2 | 145.3 Million EUR | 28.81% |
| 2019 Q3 | 106.2 Million EUR | -26.91% |
| 2019 Q1 | 112.8 Million EUR | -10.23% |
| 2018 Q3 | 137.9 Million EUR | -12.17% |
| 2018 Q1 | 116.8 Million EUR | -8.12% |
| 2018 Q4 | 125.66 Million EUR | -8.88% |
| 2018 FY | 125.66 Million EUR | -1.15% |
| 2018 Q2 | 157 Million EUR | 34.42% |
| 2017 Q4 | 127.11 Million EUR | -13.99% |
| 2017 FY | 127.11 Million EUR | 88.14% |
| 2017 Q1 | 73.2 Million EUR | 10.95% |
| 2017 Q2 | 166.8 Million EUR | 127.87% |
| 2017 Q3 | 147.8 Million EUR | -11.39% |
| 2016 FY | 67.56 Million EUR | -21.83% |
| 2016 Q3 | 93.1 Million EUR | -14.19% |
| 2016 Q2 | 108.5 Million EUR | 45.44% |
| 2016 Q1 | 74.6 Million EUR | -12.15% |
| 2016 Q4 | 65.97 Million EUR | -29.14% |
| 2015 Q4 | 84.92 Million EUR | -20.93% |
| 2015 Q3 | 107.4 Million EUR | -3.5% |
| 2015 Q2 | 111.3 Million EUR | 27.2% |
| 2015 Q1 | 87.5 Million EUR | 1.9% |
| 2015 FY | 86.42 Million EUR | -1.15% |
| 2014 FY | 87.43 Million EUR | -32.72% |
| 2014 Q4 | 85.87 Million EUR | -28.38% |
| 2014 Q3 | 119.9 Million EUR | -9.24% |
| 2014 Q2 | 132.1 Million EUR | 2.4% |
| 2014 Q1 | 129 Million EUR | -1.8% |
| 2013 FY | 129.95 Million EUR | 14.31% |
| 2013 Q4 | 131.35 Million EUR | 12.08% |
| 2013 Q2 | 140.7 Million EUR | 0.0% |
| 2013 Q3 | 117.2 Million EUR | -16.7% |
| 2012 FY | 113.68 Million EUR | 13.56% |
| 2012 Q2 | 146.1 Million EUR | 0.0% |
| 2011 Q2 | 114.4 Million EUR | 0.0% |
| 2011 FY | 100.11 Million EUR | -2.57% |
| 2010 Q2 | 127.6 Million EUR | 0.0% |
| 2010 FY | 102.75 Million EUR | 17.24% |
| 2009 FY | 87.64 Million EUR | -41.59% |
| 2009 Q4 | 87.64 Million EUR | 0.0% |
| 2008 FY | 150.05 Million EUR | -2.46% |
| 2007 FY | 153.83 Million EUR | 182.85% |
| 2006 FY | 54.38 Million EUR | -10.43% |
| 2005 FY | 60.72 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Medical Technologies Inc. | 479.63 Thousand USD | -743242.278% |
| Ansell Limited | -54.99 Million USD | 6582.732% |
| Ansell Limited | -55.1 Million USD | 6570.599% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | -36.49 Million USD | 9869.774% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | -105.1 Thousand USD | 3392328.502% |
| Psykey, Inc. | 634.59 Thousand USD | -561724.666% |
| ConvaTec Group Plc | 1.2 Billion USD | -196.959% |
| ConvaTec Group Plc | 1.2 Billion USD | -196.54% |
| Encision Inc. | 1.29 Million USD | -276131.451% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | 2.3 Million USD | -154327.762% |
| Innovative MedTech Inc. | 1.76 Million USD | -201930.219% |
| LifePoint, Inc. | -3.26 Million USD | 109330.302% |
| Medite Cancer Diagnostics, Inc. | 4.9 Million USD | -72599.178% |
| Paradigm Medical Industries, Inc. | 2.16 Million USD | -164807.493% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | -43.3 Thousand USD | 8233288.62% |
| Reflect Scientific, Inc. | -1.03 Million USD | 344471.283% |
| SmileDirectClub, Inc. | 778.67 Million USD | -357.866% |
| Sector 10, Inc. | 163 Thousand USD | -2187200.613% |
| Shandong Weigao Group Medical Polymer Company Limited | -417.55 Million USD | 953.853% |
| SheerVision, Inc. | 57.34 Thousand USD | -6216747.722% |
| United Health Products, Inc. | 660.56 Thousand USD | -539631.656% |
| Vasamed, Inc. | 22.12 Thousand USD | -16116435.575% |
| Wearable Health Solutions, Inc. | 2.63 Million USD | -135399.934% |
| Yubo International Biotech Limited | 772.27 Thousand USD | -461559.582% |